• IM/Hematology/Oncology

The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar, along with his colleagues from Surgery, Gastroenterology, Radiation Oncology and Radiology have formed multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine and pancreatic cancer. He is helping to develop the use of stromal agents and gene-targeted therapies in the treatment of pancreatic cancer and neuroendocrine tumors. Dr. Hendifar's research involves studying cachexia in his cancer patients. He has developed a treatment protocol in pancreatic cancer cachexia that will increase understanding of this phenomenon. The goal is to develop new therapies for this condition. One treatment, an anti-inflammatory agent, is already being investigated in colon cancer patients. Dr. Hendifar is also the primary investigator for several trials in the treatment of pancreatic cancer, colon cancer, and neuroendocrine tumors.

View NIH Biographical Sketch as a PDF

• Medical School: Tulane University School of Medicine, 2003
• Internship: Los Angeles County + USC Medical Center, 2006
• Residency: Los Angeles County + USC Medical Center, 2007
• Fellowship: University of Southern California, 2010

View CV as a PDF

• Cancer Institute (Samuel Oschin Comprehensive Cancer Institute)
• Gastrointestinal Oncology Center
• Pancreatic and Biliary Diseases
• Colorectal Cancer Center
• Cancer
• Medicine
• Pancreatic Cancer

• Steering Committee Member, Precision Promise Clinical Trial Consortium, 2018-present
• Member, Neuroendocrine Tumors Task Force (NET TF) of the National Cancer Institute (NCI) Gastrointestinal Steering Committee, 2018-present
• Editorial Board: Journal of Pancreatology, 2018-present
• Course Director, Gastrointestinal Cancer Conference, 2018
• Supportive Care Medicine Chair, Precision Promise Consortium, Pancreatic Cancer Action Network, 2016-present

Click here for a list of peer-reviewed publications.

• Khanuja J, Gresham G, Osipov A, Tuli R, Hendifar A. Treatment and underlying mechanisms of pancreatic cancer cachexia (PANCAX study). J Clin Oncol. 2015;33.
• Hendifar A, Osipov A, Khanuja J, Nissen N, Naziri J, Yang W, Li Q, Tuli R. Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma. PLoS One. 2016 Mar 25;11(3):e0152172.
• Singhi AD, Ali SM, Lacy J, Hendifar A, Nguyen K, Koo J, Chung JH, Greenbowe J, Ross JS, Nikiforova MN, et al. Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2017 May;15(5):555-562. PubMed PMID: 28476735.